WO2006081320A2 - Preparation pharmaceutique - Google Patents

Preparation pharmaceutique Download PDF

Info

Publication number
WO2006081320A2
WO2006081320A2 PCT/US2006/002696 US2006002696W WO2006081320A2 WO 2006081320 A2 WO2006081320 A2 WO 2006081320A2 US 2006002696 W US2006002696 W US 2006002696W WO 2006081320 A2 WO2006081320 A2 WO 2006081320A2
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
temperature
active agent
protein active
agent
Prior art date
Application number
PCT/US2006/002696
Other languages
English (en)
Other versions
WO2006081320A3 (fr
Inventor
James D. Colandene
Thomas M. Spitznagel
Alma Creagh
John S. Vrettos
Linda M. Maldonado
Melissa D. Perkins
Adeola O. Grillo
Original Assignee
Human Genome Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences, Inc. filed Critical Human Genome Sciences, Inc.
Publication of WO2006081320A2 publication Critical patent/WO2006081320A2/fr
Publication of WO2006081320A3 publication Critical patent/WO2006081320A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the invention relates to the lyophilization or freeze-drying of a liquid formulation. More particularly, the invention provides an improved process for lyophilization or freeze-drying a liquid pharmaceutical formulation that includes a protein- based active agent.
  • the stability and/or potency of many pharmaceutical and food products can be adversely affected during long-term storage. Loss of potency may be attributable to direct chemical degradation, structural and/or physical alteration.
  • degradative chemical reactions include, but are not limited to, hydrolysis, oxidation, isomerization, deamidation, disulfide scrambling, and racemization.
  • structural or physical alterations include, but are not limited to, denaturation, aggregation, precipitation and polymerization.
  • Lyophilization also called freeze-drying refers to a process that uses low temperature and pressure to remove a solvent, typically water, from a liquid formulation by the process of sublimation (i.e., a change in phase from solid to vapor without passing through a liquid phase). Lyophilization helps stabilize pharmaceutical formulations by reducing one or more solvent components to levels that no longer support significant rates of chemical or physical degradation.
  • freeze-drying can effectively enhance protein stability
  • freeze-drying can also significantly increase the time and cost of the overall fill-finish process because freeze-drying requires additional handling and processing and requires complex and expensive equipment. In some cases, lyophilization can cost upwards of $100k/day.
  • One way in which the cost of freeze-drying can be reduced is to reduce the processing time, for example, by exposing the formulation to as high a temperature as possible during primary drying. For example, a 5°C increase in temperature can decrease the drying time by a factor of two. However, excessive temperature can result in a final product with undesirable qualities, for example, cake collapse. Conventionally, it is thought that the primary drying process should be performed at a temperature below the glass transition temperature (Tg') or collapse onset temperature (To) of the formulation to prevent collapse.
  • Tg' glass transition temperature
  • To collapse onset temperature
  • Tg' of the formulation.
  • the formulation can be dried at a higher temperature, thereby decreasing the processing time.
  • collapse temperature is increased by including a crystalline bulking agent, such as mannitol or glycine, in the formulation.
  • a crystalline bulking agent such as mannitol or glycine
  • the presence of a disaccharide stabilizing agent in a formulation may interfere with crystallization of the crystalline bulking agent.
  • an isotonic formulation that includes a concentration of stabilizing agent, for example, a mono-, di- or poly- saccharide stabilizing agent, that is greater than about 3% w/v
  • a concentration of stabilizing agent for example, a mono-, di- or poly- saccharide stabilizing agent, that is greater than about 3% w/v
  • the addition of a crystalline bulking agent such as glycine or mannitol may not be effective to increase the Tg' or the collapse temperature of the formulation.
  • the amount of stabilizing agent in the formulation needs to be at least 3% w/v to provide protein stability. Therefore, there still remains a need for a cost-effective freeze-drying process, particularly for formulations that lack a crystalline bulking agent or contain a limited amount of crystalline bulking agent.
  • One aspect of the invention relates to the discovery that a pharmaceutical formulation can be lyophilized at a temperature during the primary drying stage that is above the glass transition temperature (Tg 1 ) of the formulation, but below the collapse temperature (Tc), while retaining desirable properties of the final freeze-dried product, including, but not limited to visual appearance, stability, and biological activity.
  • Another aspect of the invention relates to the discovery that a pharmaceutical formulation can be lyophilized at a temperature during the primary drying stage that is above the collapse onset temperature (To) but below the collapse temperature.
  • Another aspect of the invention relates to the discovery that increasing the protein concentration of a pharmaceutical formulation increases the difference between Tg' and Tc.
  • another aspect of the invention provides a liquid pharmaceutical formulation suitable for freeze-drying to form a lyophilized formulation, wherein the liquid formulation includes a protein concentration of at least about 20 mg/mL, 40 mg/mL, 50 mg/mL, 60 mg/mL, 70 mg/mL, 80 mg/mL, 90 mg/mL, 100 mg/mL, 125 mg/mL, 150 mg/mL, or higher.
  • the liquid formulation includes little or no crystalline bulking agent (i.e., the bulking agent is present in a minor amount, such that the bulking agent is unable to form a crystalline supporting structural matrix during lyophilization).
  • the liquid formulation includes crystalline bulking agent and amorphous solute at a weight:weight ratio of less than 1.0, 0.9, 0.75, or 0.50.
  • the liquid formulation includes at least about 2%, 3%, 4%, 5%, 10%, or 15% w/v stabilizing agent, such as a disaccharide stabilizing agent, including, but not limited to sucrose or trehalose.
  • FIGURE 1 is a graph showing the change in heat capacity ( ⁇ Cp) at the glass transition temperature (Tg).
  • FIGURE 2 is a graph showing the exothermic transition observed when a crystalline component melts.
  • FIGURE 3 shows the Tg' of a sample monoclonal antibody at varying concentrations, as determined by differential scanning calorimetry (DSC).
  • FIGURE 4 shows the collapse temperature compared to the Tg' of a sample monoclonal antibody at varying concentrations.
  • FIGURE 5 shows a FTIR Spectrum comparing Aggressive and Conservative Cycles.
  • FIGURE 6 shows a FTIR FDP-minus-BDS Difference Spectra for monoclonal antibody cycles.
  • FIGURE 7 shows a lyophilization cycle for a sample monoclonal antibody at 80 mg/mL.
  • FIGURE 8A-D shows a Freeze-Dried Microscopy image (10x magnification) of the monoclonal antibody (80 mg/mL) showing the change in microstructure as temperature is increased over time at a rate of 1°C per minute under vacuum:
  • Figure 9 is a photograph showing cakes of freeze-dried BSA (0 mg/mL - 100 mg/mL) and sorbitol containing formulations.
  • FIGURE 10 is an illustration of the structural support matrix provided by a crystalline bulking agent during primary drying.
  • Lyophilization also called freeze-drying refers to a process that uses low temperature and pressure to remove a solvent, typically water, from a liquid formulation by the process of sublimation (i.e., a change in phase from solid to vapor without passing through a liquid phase). Lyophilization helps stabilize pharmaceutical formulations by reducing one or more solvent components to levels that no longer support chemical reactions or biological growth.
  • Freeze-drying processes are known. In some instances, freeze-drying is performed in a "manifold” process in which flasks, ampules or vials are individually attached to the ports of a manifold or drying chamber. In other instances, freeze-drying is performed as a "batch” process in which one or more similar sized vessels containing like products are placed together in a tray dryer, hi a "bulk” process, the product is poured into a bulk pan and dried as a single unit. The product is removed from the freeze drying chamber prior to closure and then packaged in air-tight containers.
  • the invention described herein can be used in combination with any of these processes.
  • lyophilization takes place in at least three stages: freezing; primary drying; and secondary drying, hi some instances, it may be desirable to include an annealing step between the freezing and primary drying stages.
  • freezing primary drying
  • secondary drying hi some instances, it may be desirable to include an annealing step between the freezing and primary drying stages.
  • a liquid solution or formulation that contains at least one solvent and at least one solute is placed in a container, which is then placed in a freeze-dryer.
  • the primary goal of the freezing process is to solidify at least the solvent component of the formulation.
  • an amorphous system A formulation in which at least some of the solute remains in an amorphous state is referred to herein as "an amorphous system.”
  • an amorphous system is a liquid formulation that contains protein as an active agent.
  • Tg' the glass transition temperature of the maximally freeze concentrated solution
  • the crystalline component may also contain crystalline excipients, for example crystalline bulking agents such as mannitol or glycine.
  • crystalline excipients for example crystalline bulking agents such as mannitol or glycine.
  • concentration of the solute that remains amorphous increases as the temperature of the formulation is decreased and the solvent crystallizes out of solution.
  • the amorphous component includes the amorphous active agent, for example, a protein, and any amorphous excipients, for example, a disaccharide stabilizing agent.
  • a component of a formulation such as a bulking agent, can exist in a crystalline or an amorphous state depending upon the formulation and/or the processing parameters.
  • a "frozen" amorphous system contains a crystalline component, which can include the crystalline solvent and crystalline excipients; and an amorphous component located within the interstitial regions of the crystalline component.
  • the amorphous component can include the amorphous active agent; one or more amorphous excipients; and any remaining unfrozen solvent.
  • nucleation temperature The temperature at which nucleation occurs
  • the nucleation temperature can affect primary drying rate and morphology. As the temperature decreases, the probability of nucleation temporarily increases. However, as the temperature is decreased further, nucleation tends to decrease due to the increased viscosity of the system.
  • the nucleation temperature can be affected by environmental particulates, freezing method and the presence or absence of nucleating agents.
  • heterogeneous nucleation refers to nucleation that was initiated by foreign particles (also called nucleation sites) in the solution or on the surface of the container in which the solution was placed.
  • homogenous nucleation refers to nucleation that occurs in the absence of a nucleation site in the solution. Generally, homogeneous nucleation is caused by the aggregation of slow moving molecules. The nucleation observed in pharmaceutical solutions is largely heterogeneous. [0032] The rate and method of cooling can influence the structure and appearance of the matrix and final product. For example, if the solution is frozen quickly, the crystals will tend to be small.
  • Supercooling is another physical event that is observed during the freezing process (in addition to solvent crystallization; concentration of solutes; and in some cases, crystallization of one or more solutes).
  • the term “supercooling” refers to the reduction of the temperature of a liquid beyond its freezing point. As a result of supercooling, the product temperature may have to be decreased significantly below the actual freezing point of the solution before freezing occurs.
  • the freezing process is typically performed at a temperature below at least about 0°C, below at least about -10 0 C, below at least about - 25°C, below at least about -40 0 C, or below at least about -50°C.
  • the freezing process is performed at atmospheric pressure.
  • the rate at which the temperature of the formulation is reduced is referred to herein as the "freezing rate.”
  • the freezing rate for a formulation is more typically between about 0.05 0 C to about 5.0°C per minute, about 0.1 0 C to about LO 0 C per minute, or about 0.3°C to about 0.4°C per minute in production scale freeze-dry cycles.
  • Some freeze-dry cycles contain an annealing or thermal treatment step following freezing.
  • an annealing step the temperature of the frozen formulation is increased temporarily and then, after a specified period of time, the temperature is again lowered.
  • Annealing may be used for different purposes.
  • An annealing step may be included to control the nucleation temperature of the formulation, which may affect the primary drying rate and resulting cake morphology.
  • annealing can increase the primary drying rate of a frozen formulation between about 1 and 5 fold.
  • An annealing process generally results in the removal of solvent crystals smaller than a critical size and generation of larger solvent crystals. The increased crystal size may result in an increased primary drying rate because pores in the material left by large crystals generally provide less resistance to primary drying than smaller pores left by smaller crystals.
  • Annealing is particularly beneficial for crystallizing excipients and bulking agents present in the formulation. In particular, annealing promotes crystallization of crystalline bulking agents such as mannitol or glycine.
  • an annealing process involves maintaining a sample below its freezing point, but above the Tg' of the material, for a predetermined period of time, for example, to increase the rate of the annealing process. Because the solvent is already substantially frozen prior to the annealing process, and because, unlike in primary drying, the solvent is not being removed, the annealing process can be performed at a relatively high temperature without adversely affecting the quality of the final product.
  • the processing parameters of the annealing step depend on the formulation, the annealing step is generally performed at a temperature between about - 5O 0 C and about 0 0 C, about -40°C and about -5°C, about -30 0 C and about -5°C, about - 25 0 C and about -10 0 C, or about -20 0 C and about -10 0 C, for a time ranging between a few minutes to a few days, typically between about 15 minutes and about 24 hours, or between about 15 minutes and about 10 hours.
  • an annealing step may not be necessary. However, in some cases it may still be desirable to include an annealing step.
  • solvent is removed from the formulation by a process of sublimation.
  • sublimation refers to the transition of a solid to a gas, without passing through a liquid stage.
  • One goal of the primary drying process is to remove all of the "mobile" solvent from the formulation. Although a majority (i.e., at least about 50 wt%) of the solvent is removed from the formulation during primary drying, the formulation that remains at the end of the primary drying process includes an amorphous component within a glassy matrix that contains between about 5 wt% and about 49 wt% solvent, more typically between about 10 wt% and about 40 wt% solvent, or between about 10 wt% and about 20 wt% solvent. Although the composition of the liquid formulation can affect the cycle time, as well as the desired amount of solvent in the final product, primary drying can take as little as 1 hour, more typically between about 5 hours and about 10 days, or between about 1 day and about 4 days.
  • the primary drying process is performed at a reduced pressure (i.e., vacuum) and at a temperature higher than the temperature at which the system was frozen.
  • the increase in temperature provides energy for sublimation.
  • primary drying at lower temperatures tends to increase cycle length, which usually results in a more expensive process.
  • the term "temperature” can refer to the “shelf temperature” or the “product temperature.”
  • shelf temperature refers to the temperature of the lyophilization equipment.
  • product temperature refers to the actual temperature of the formulation.
  • the shelf temperature influences the product temperature, the shelf temperature and the product temperature can differ for a variety of reasons. For example, because sublimation is an endothermic process, as the solvent sublimes the remaining amorphous component of the formulation tends to cool. Consequently, throughout primary drying, the amorphous solid tends to remain colder than the shelf temperature.
  • Maximum product primary drying temperature is defined as the maximum temperature that the product encounters before primary drying is complete. It may be measured with product thermocouples as a point of inflection in the thermocouple trace when ice sublimation is complete and the product temperature begins to rise. The asymptotic rise in temperature may be used to approximate the endpoint of primary drying. Shelf temperature is used as the primary control of product temperature during primary drying and it typically ranges from about — 30°C to about 1O 0 C for protein formulations although the desired product temperature depends on the formulation.
  • Important temperature-related properties of a formulation include the “eutectic temperature” (Te), the “glass transition temperature” (Tg), the “collapse temperature” (Tc), the “onset temperature” (To), and the melting temperature (Tm).
  • Te eutectic temperature
  • Tg glass transition temperature
  • Tc glass transition temperature
  • Tc onset temperature
  • Tm melting temperature
  • Tm refers to the melting temperature of the solvent itself (e.g., ice).
  • the eutectic temperature refers to the temperature in a freezing process at which both the solute and solvent present in a crystalline system become frozen or crystalline or the temperature at which the solute has been freeze-concentrated to saturation.
  • crystalline or “crystal” refers to a solid in which the constituent atoms, molecules or ions are packed in a regularly ordered, repeating pattern extending in all three spatial dimensions. Under some conditions, the solid may include a single crystal, where all of the atoms in the solid fit into the same lattice or crystal structure. However, it is more typical that many crystals form simultaneously during solidification, leading to a polycrystalline solid.
  • the term "crystalline system” refers to a mixture in which all components, i.e., both the solvent and solute form crystals.
  • Te has been used as a guide for determining the maximum product temperature for a crystalline system during primary drying. It is generally thought that the desirable properties of a freeze-dried product may be lost if the product temperature exceeds the eutectic temperature while the frozen solvent is still present because drying will take place from the liquid state instead of the solid state.
  • Tg glass transition temperature
  • the amorphous component is a solid, but unlike a crystalline solid, there is no distinct order of the positions of the atoms, molecules or ions.
  • An example of an amorphous system is a protein-based formulation. In protein-based pharmaceutical formulations, the amorphous component contains at least the protein active agent. The amorphous component may also contain one or more excipients.
  • the glass transition temperature represents the maximum allowable temperature during the primary drying of the amorphous system, unless there is a substantial amount of crystalline bulking agent also present to support the cake.
  • the glass transition temperature can be defined empirically as the temperature at which the viscosity of the liquid exceeds a certain value, for example, 10 13 Pascal seconds.
  • the glass transition temperature can be determined experimentally, for example, by Differential Scanning Calorimetry (DSC). DSC is a technique used to study thermal transitions of a system.
  • thermal transition refers to a change in state, for example, the change from a solid to a liquid, as a consequence of a change in temperature.
  • the heat capacity, or C p is the amount of heat required to raise the temperature of a specified unit mass of substance by one degree Celsius.
  • the heat capacity of the amorphous component of the frozen formulation changes.
  • the glass transition temperature for an amorphous system is not a single temperature point, but rather a range of temperatures, usually within a range of 1°C to 2 0 C. Li many instances, the viscosity of the amorphous component changes by three or four orders of magnitude over a temperature range of a few degrees at temperatures around the glass transition temperature.
  • DTA Differential Thermal Analysis
  • ER Electrical Resistance
  • the collapse temperature refers to the temperature at which an increase in mobility or viscous flow of the amorphous component within the interstitial regions of the crystalline component is observed. If the collapse temperature is exceeded during primary drying, the microscopic structure of the amorphous component of the formulation that was formed during freezing and sublimation may be lost. [0051]
  • the collapse temperature is a function of all components present in the formulation and can therefore vary depending on the formulation. The collapse temperature may also be affected by the measurement method and the amount of residual unfrozen solvent contained in the amorphous component. Additionally, within a given system or formulation, as solvent is reduced via sublimation, the collapse temperature tends to increase.
  • the collapse temperature is often equated with the glass transition temperature, they are not actually equivalent.
  • the glass transition temperature is measured in a closed system of constant composition, whereas collapse is a dynamic process that can occur during the drying process.
  • Tg' and Tc for a particular formulation may differ by a few degrees (i.e., between about 2 0 C to about 3°C).
  • increasing the protein concentration in the liquid formulation can substantially increase the difference between Tg' and Tc.
  • the difference between Tg' and Tc can be as much as 1O 0 C, 15°C, or 20°C, for example, in a formulation containing disaccharide as the principle lyo-/cryo- protectant.
  • the difference may even be higher for other formulations, for example, those containing sorbitol as the principle lyo-/cryo-protectant.
  • collapse is associated with a decreased surface area of the freeze- dried formulation, reduction in cake volume, and/or loss of pharmaceutical elegance.
  • the term “collapse” may refer to collapse of the lyophilized product as observed by freeze- dried microscopy in which the initial structural appearance after freezing the product is lost at the drying front during warming of the microscope stage.
  • the term “collapse” may also refer to collapse of the lyophilized product (or cake) during lyophilization in a freeze dryer (e.g., lab-scale or production-scale).
  • the collapse temperature as determined by freeze-dry microscopy is thought to be the same or similar (within a few degrees) to that of the collapse temperature observed within the freeze-dryer.
  • the term "collapse" in the context of lyophilization in a freeze-dryer refers to a reduction of cake volume of at least about 10%, 25%, 50%, 75%, 85%, 95% or 100%.
  • the reduction in cake volume can be measured using known methodologies, including but not limited to, visual inspection or BET surface area analysis. Collapse may also be associated with a glossy or glassy appearance of the cake and/or an increase in reconstitution time.
  • the loss of crystal structure can be observed using differential scanning calorimetry (DSC).
  • DSC differential scanning calorimetry
  • the "melting" or collapse of the crystal structure is an endothermic transition that can be observed by a "dip” in a plot of heat flow versus temperature (See Figure 2).
  • Freeze-dried microscopy can be used to visually observe structural changes of the formulation as the temperature is increased. Generally, during primary drying a receding boundary can be observed as the frozen layer decreases in thickness and the thickness of the partially dried solids increases (See Figure 8A-D).
  • the collapse of a pharmaceutical product can be merely an aesthetic problem. In other cases, collapse can result in rejection of the product. Generally, when a cake collapses, solvent may become trapped within the cake and may not be removed during secondary drying. This is generally undesirable because the additional residual solvent or moisture may reduce the stability of the final freeze-dried product. Collapse may also make the final product visually unappealing and harder to reconstitute. Difficulty in reconstituting the drug at the user stage may result in partial drug loss to the patient since many reconstituted lyophilized products are pre-filtered before administration and drug product that is not dissolved may become trapped in the filter.
  • the desirable properties of a freeze-dried formulation are related to the microstructure formed during the freezing process. It is therefore desirable to maintain the microstructure of the formulation throughout the drying processes.
  • the temperature of an amorphous system should be held below the glass transition temperature (Tg') of the formulation or below the collapse onset temperature during primary drying such that the viscosity of the amorphous component is high enough to retain the structure of the amorphous component throughout the drying process.
  • the term "collapse onset temperature” refers to the temperature at which an initial structural change in the microstructure of the freeze-dried product is detected, for example, by freeze-dried microscopy. To may occur at a temperature around or above the Tg' but below the Tc. Conventionally, the maximum product temperature targeted during primary drying is below To-
  • FIG. 8 shows a sequence in time (Panels A-D) in which a monoclonal antibody formulation (at a concentration of 80 mg/mL) is freeze-dried while gradually increasing the temperature. Frozen material is on the right side of each panel and dried material is on the left. When panels A-D are viewed in sequence, the drying front is gradually moving from left to right.
  • the "initial structural change" in the microstructure of the freeze-dried product typically appears as a change in the initial appearance.
  • the precise change in appearance that occurs depends on many factors, for example, the components of the formulation.
  • a person experienced with freeze-dry microscopy, particularly with respect to observing the changes that occur during lyophilization, is able to detect and interpret such changes in appearance.
  • the appearance gradually changes further, until a distinctly different appearance is evident, and the original structure is gone (i.e., collapse).
  • Pressure can affect the drying rate during primary drying. Generally, the rate of sublimation from a frozen solid depends upon the difference in vapor pressure of the solid compared to the vapor pressure of the chamber. The pressure differential is important because molecules migrate from the high-pressure crystalline component to the low pressure chamber.
  • the primary drying process is typically performed at a reduced pressure (i.e., under a vacuum). More typically, the chamber pressure is reduced to a pressure that is below the vapor pressure of the solvent component. Because the vapor pressure of the solvent component can vary depending on the formulation, the pressure at which the primary drying process is performed can vary, but is typically .
  • chamber pressure is usually set between about % and about 1 A of the vapor pressure of the solvent at the desired product temperature.
  • Suitable inert gasses are known and include, for example, nitrogen.
  • the presence of the inert gas molecules facilitates heating of the walls of the container in addition to conduction through the bottom of the container, thereby increasing the amount of heat being supplied to the product per unit time. This enhances the drying rate, reduces the cycle time and reduces energy and labor costs associated with a lengthy process.
  • One aspect of the invention relates to the discovery that a pharmaceutical formulation can be lyophilized at a temperature during the primary drying stage that is above the glass transition temperature (Tg') of the formulation, but below the collapse temperature (Tc), while retaining desirable properties of the final freeze-dried product, including, but not limited to visual appearance, stability, and biological activity.
  • retention of such desirable properties is related to retention of the microscopic structure of the formulation that is formed during primary drying, for example, good cake structure that has relatively good porosity and retains pharmaceutical elegance, which allows for efficient secondary drying and low residual moisture.
  • Another aspect of the invention relates to the discovery that a pharmaceutical formulation can be lyophilized at a temperature during the primary drying stage that is at or above the collapse onset temperature (To), but below the collapse temperature (Tc).
  • Another aspect of the invention relates to the discovery that increasing the protein concentration of a pharmaceutical formulation increases the difference between Tg' and Tc, and the difference between To and Tc.
  • the difference between Tg' and Tc is generally in the range of about 0°C to about 2°C.
  • the difference between Tg' and Tc may increase to within the range of about 2°C to about 10°C.
  • the difference between Tg' and Tc can be greater than about 10°C, for example, between about 10°C to about 2O 0 C.
  • another aspect of the invention provides a liquid pharmaceutical formulation suitable for freeze-drying to form a lyophilized formulation, wherein the liquid formulation includes a protein concentration of at least about 20 mg/mL, 40 mg/mL, 50 mg/mL, 60 mg/mL, 70 mg/mL, 80 mg/mL, 90 mg/mL, lOO mg/mL, 125 mg/mL, 150 mg/mL, or higher.
  • the liquid formulation includes little or no crystalline bulking agent (i.e., the crystalline bulking agent is present in a minor amount such that the crystalline bulking agent does not form a supporting structural matrix during lyophilization).
  • the liquid formulation includes crystalline bulking agent and amorphous solute at a weightrweight ratio of less than 1.0, 0.9, 0.75, or 0.50.
  • the liquid formulation includes at least about 2%, 3%, 4%, 5%, 10%, 15% w/v stabilizing agent, such as a mono-, di-, or polysaccharide stabilizing agent, including, but not limited to sucrose, trehalose, dextran, and glucose.
  • stabilizing agents may include sugar alcohols and amino acids, providing that they are retained in an amorphous phase after freeze-drying, including, but not limited to mannitol, sorbitol, and glycine.
  • Secondary drying includes the removal of non-frozen water that is bound or adsorbed to the amorphous solid matrix (i.e., the protein and other solutes in the formulation). This is mainly a diffusion-based process that is primarily driven by product temperature and not by chamber pressure. Therefore, it is typically performed using a shelf temperature significantly higher than that used during primary drying. [0066] The goal of the secondary drying process is to obtain a porous "freeze-dried formulation,” also referred to as a "cake” with a level of residual moisture that no longer supports chemical or physical degradation. As used herein, the term “freeze-dried formulation” or “cake” refers to the dried formulation that remains after the solvent has been removed by the process of lyophilization.
  • the freeze-dried formulation typically includes an amorphous solid matrix and a minor amount of unfrozen solvent.
  • the amorphous solid matrix contains the active agent and excipients. It is worthwhile to note that the amorphous solid matrix can include both crystalline and amorphous excipients.
  • the freeze-dried formulation has a moisture content below about 5 wt%, typically between about 0 wt% and about 3 wt%. Residual moisture of less than 1% in a protein formulation is generally considered low.
  • the shelf temperature may be increased during secondary drying without altering the structure of the resulting cake (i.e., causing melting). Additionally, the solvent remaining during secondary drying is typically more strongly bound to the amorphous solid matrix, and consequently may require more energy for its removal. Thus, during the secondary drying process, the shelf temperature is typically increased and the chamber pressure is decreased.
  • a higher temperature results in a faster drying rate.
  • Tg generally increases. This may allow the temperature to be increased further.
  • it is still important that the formulation remain below a certain temperature during the secondary drying process a temperature that is too high may result in collapse of the product.
  • a secondary drying process is performed at a temperature between about — 20°C and about 50°C, or between about 0 0 C and about 40 0 C, or between about 10°C and about 40°C.
  • Typical secondary drying temperatures for protein formulations range between about 20°C and about 4O 0 C.
  • the heating rate i.e., the rate at which the temperature is raised from the primary drying temperature to the secondary drying temperature
  • the heating rate is similar to the freezing rate. Consequently, the heating rate (determined by the change in shelf temperature) from primary drying to secondary drying is between about 0.05°C to about 5.0 0 C, between about 0.1°C to about 1.0°C, or between about 0.3 0 C to about 0.4 0 C per minute.
  • most freeze dryers when occupied with product, are capable of a faster heating rate than freezing rate (generally due to the reduction in amount of solvent present in the dried product as compared to the liquid product), it is not always advantageous to have the most rapid heating rate. For example, a low heating rate may allow some secondary drying to occur prior to reaching the secondary drying shelf temperature.
  • the secondary drying process is performed under a vacuum, at about the same pressure as the primary drying process, typically between about 40 mTorr and about 400 mTorr, or between about 50 mTorr and about 250 mTorr.
  • lyophilization is a process in which a liquid formulation is subjected to a freeze-dry process to obtain a freeze-dried formulation.
  • the contents of a freeze-dried formulation may vary depending upon the active agent and the intended route of administration.
  • the liquid formulation generally includes a solvent and solute.
  • the solute typically includes an active agent and, optionally, one or more excipients.
  • the resulting freeze-dried formulation includes an amorphous solid matrix and a minor amount of residual unfrozen solvent.
  • the amorphous solid matrix includes the active agent and, optionally, one or more excipients.
  • excipients any component in the formulation that is not the solvent or the active agent is referred to as an "excipient.”
  • Excipients are included in a formulation for many reasons, although the primary function of many excipients is to provide a stable liquid environment for the active ingredient or to protect the active agent during the freezing or drying process. Some excipients may be used to achieve multiple effects in a formulation. For example, a disaccharide such as sucrose may act as a cryoprotectant, lyoprotectant, bulking agent and tonicity modifier. Behavior of an excipient may change when in the presence of other excipients. Some combinations have a positive synergistic effect, others have a negative synergistic effect.
  • Positive synergy occurs when the sum of the effects of excipients acting together is greater than the additive effects of the individual excipients. Negative synergy occurs when the sum of effects of the combination of excipients is less than that of the individual excipients. Examples of active agents, solvents and excipients are provided below.
  • the term "pharmaceutical formulation” refers to both formulations that include active agents that are small molecule therapeutics and formulations that include a biopharmaceutical as an active agent.
  • small molecule therapeutics refers to natural and synthetic substances that typically have a low molecular weight (i.e., less than about 1000 Daltons). Small molecules can be isolated from natural sources such as plants, fungi or microbes, or they can be synthesized by organic chemistry. Many conventional pharmaceuticals, such as aspirin, penicillin, and chemotherapeutics, are small molecules.
  • biopharmaceutical refers to formulations containing active agents that generally have a high molecular weight (i.e., at least about 1000 Daltons).
  • active agents include carbohydrates, polypeptides, and proteins.
  • polypeptide or “protein” as used herein can refer to both antibody and non-antibody proteins.
  • Non-antibody proteins include, but are not limited to, proteins such as secreted proteins, enzymes, receptors, and fragments or variants thereof.
  • the polypeptide may or may not glycosylated.
  • polypeptide or “protein” may also include multimeric proteins, such as hetero- or homo-dimers, trimers, etc.
  • antibodies can include both monoclonal and polyclonal antibodies, antibody fragments, chimeric antibodies, human or humanized antibodies.
  • Antibody fragments are known and include, but are not limited to, single chain antibodies, such as ScFv, Fab fragments, Fab 1 or F(ab') 2 fragments, etc. Although antibodies tend to have a higher molecular weight than non-antibody proteins, the discoveries of the invention (e.g., those relating to drying above the Tg', especially for formulations with increased protein concentration as described herein, formulations containing little or no crystalline bulking agent and/or formulations containing at least about 2 % w/v disaccharide stabilizing agent) can be applied to both.
  • lyophilization is the process by which solvent is removed from a liquid formulation.
  • solvent refers to the liquid component of a formulation that is capable of dissolving or suspending one or more solutes.
  • solvent can refer to a single solvent or a mixture of solvents.
  • a commonly used solvent for pharmaceutical formulations is water for injection (WFI).
  • WFI water for injection
  • Suitable organic solvents include, but are not limited to, acetonitrile, methanol, ethanol, propanol, tert-butyl alcohol, acetone, cyclohexane, and dimethylsulfoxide (DMSO).
  • the purpose of the bulking agent is to provide bulk to the formulation and enhance cake formation.
  • the term “bulking agent” includes both “crystalline” and “non-crystalline” bulking agents.
  • crystalline bulking agents refer to bulking agents that are capable of forming a crystal structure under typical lyophilization conditions.
  • a crystalline bulking agents refers to a bulking agent that is capable of crystallizing during freezing (e.g., between a temperature of about O 0 C and about - 50°C).
  • a crystalline bulking agent may require an annealing or thermal treatment step to promote crystallization during the freezing process. It is worthwhile to note that a bulking agent may or may not crystallize during lyophilization, depending upon the conditions of the lyophilization process and/or the other excipients present in the formulation.
  • the crystalline bulking agent may form a structural support matrix for the amorphous component of the formulation.
  • structural support matrix refers to the support that the crystalline structure provides to the formulation (analogous to a "scaffolding"), such that the macrostructure of the cake is largely unaffected by any "microcollapse" of the amorphous solute residing within the interstices of the structural support matrix during primary drying.
  • This crystalline structural support matrix may allow for primary drying with a product temperature above the Tg' of the amorphous component of the product.
  • a crystalline bulking agent can provide a structural support matrix (10) for an amorphous solute (15) contained within the interstices (12) of the structural support matrix (10).
  • microcollapse refers to a change in the structure (e.g., collapse) of the amorphous solute residing within the interstices of the crystalline bulking agent structural support matrix that does not result in a change in the structure of the overall freeze-dried formulation or cake.
  • crystalline bulking agents may improve cake structure, for example, by providing a structural support matrix during primary drying, it may not always be desirable to include a crystalline bulking agent in a formulation.
  • crystalline bulking agents may reduce protein stability both during lyophilization and during storage (see discussion of stabilizing agents below).
  • stabilizing agent for example, a mono-, di-, or poly- saccharide stabilizing agent
  • crystalline bulking agent include, but are not limited to, glycine and mannitol. Mannitol is a naturally occurring carbohydrate classified as a sugar alcohol or polyol. Glycine is a neutral amino acid.
  • non-crystalline bulking agent refers to any component of the formulation that provides bulk to the formulation but does not crystallize under typical lyophilization conditions.
  • non-crystalline bulking agent will generally remain amorphous (i.e. not form a crystal structure) when cooled below O 0 C.
  • non-crystalline bulking agents include monosaccharides, disaccharides, dextran, and polysaccharides. Additional non-crystalline bulking agents also may include amino acids, polypeptides, and proteins.
  • the primary drying step is carried out at a temperature above Tg' or at or above about T 0 for the formulation and below Tc.
  • the rate of primary drying can be increased without including a crystalline bulking agent in the formulation. Therefore, in one embodiment, the formulation does not include a sufficient amount of crystalline bulking agent to form a structural support matrix.
  • the amount of crystalline bulking agent that is "sufficient to form a structural support matrix" can vary depending upon the type of crystalline bulking agent, e.g., glycine versus mannitol (generally glycine forms crystals more readily and therefore will tend to crystallize even when included at a lower concentration).
  • a crystalline bulking agent is generally able to provide a "structural support matrix" when the formulation includes a ratio of crystalline bulking agent to amorphous solute of at least about 1.0.
  • the crystalline bulking agent may not crystallize, only partially crystallize or only form "pockets" of crystals, rather than forming a crystalline support matrix.
  • the formulation includes a weightweight ratio of crystalline bulking agent to amorphous solute of less than about 1.0, about 0.9, about 0.75 or about 0.50. As discussed below, the reduction in the amount of crystalline bulking agent in the formulation can result in improved lyoprotection and/or cryoprotection of the active agent.
  • Stabilizing agents are typically added to a formulation to improve stability of the protein formulation, for example, by reducing denaturation, aggregation, deamidation and oxidation of the protein during the freeze-drying process as well as during storage.
  • stabilizing agents include cryoprotectants and lyoprotectants.
  • cryoprotectant refers to compounds that protect the active agent during freezing.
  • lyoprotectant refers to compounds that protect the active agent during drying.
  • Saccharides including monosaccharides such as glucose, disaccharides such as sucrose (glucose + fructose), lactose (glucose + galactose), maltose (glucose + glucose) trehalose (alpha-D-glucopyranosyl alpha-D-glucopyranoside), and polysaccharides such as dextran (polysaccharide containing glucose monomers) are commonly used stabilizing agents.
  • Glucose, lactose and maltose are reducing sugars and can reduce proteins by means of the mailard reaction.
  • Disaccharides such as sucrose, trehalose, and polysaccharides, such as dextran, are non-reducing sugars.
  • Sugar alcohols such as mannitol and amino acids such as glycine have conventionally been used as crystalline bulking agents to provide a rigid cake support. However, they may be used as a stabilizing agent, if they remain in an amorphous phase following the freeze-dry process.
  • the hydrogen-bonding theory postulates that the disaccharide stabilizer is able to form hydrogen bonds with protein (similar to the replaced water) which, in turn, prevents protein denaturation. This is also called the water replacement hypothesis.
  • the preferential exclusion hypothesis postulates that the stabilizing agent is preferentially excluded from protein surface and destabilizes the unfolded state more than the folded state. Thus, the thermodynamics of the system drives the protein towards the folded (native) state.
  • a final hypothesis is the vitrification hypothesis which postulates that disaccharides form sugar glasses of extremely high viscosity. The protein and water molecules are immobilized in the viscous glass, leading to extremely high activation energies required for any reactions to occur. It is believed that stabilizing agents are able to hydrogen bond with the protein and thus prevent denaturation
  • a crystalline bulking agent may become separated from the amorphous solute, for example, as the bulking agent crystallizes, the amorphous solute becomes trapped within the interstices of the crystalline structure. Consequently, the crystalline bulking agent is no longer able to stabilize the active agent by hydrogen bonding, preferential exclusion, or vitrification. Additionally, a crystalline bulking agent may form crystals during storage, which can result in reduced protein stability. Tonicity/Osmostic Pressure
  • Osmolar concentration can be expressed in two ways: osmolality, which is expressed as mmol/kg of solvent and osmolarity, which is expressed as mmol/1 of solution.
  • Osmolality is a thermodynamically more precise expression because solution concentrations expressed on a weight basis are temperature independent while those based on volume will vary with temperature in a manner dependent on the thermal expansion of the solution.
  • tonicity is a physical property dependent on the total number of solute particles present in a solution whereas tonicity is a physiological process dependent upon the selectively permeable characteristics of a membrane.
  • tonicity refers to the osmotic pressure of a solution due to concentration of particles that do not penetrate a cell membrane.
  • an isotonic solution has the same osmotic pressure as the interior of a cell, such that the cell volume is not affected when placed in an isotonic solution.
  • a hypotonic solution when placed in a hypotonic solution, a cell will swell, due to the influx of solvent.
  • osmolality of body fluids is tightly regulated. Normal serum osmolality lies between 285 mOsm and 290 mOsm. Because movement of solvent from solutions having a low osmotic pressure to solutions having a high osmotic pressure can cause severe physiological problems, including cell dehydration (crenation) or expansion of the cell until it breaks open (lysis), osmotic pressure is an important consideration when preparing a pharmaceutical formulation.
  • the tonicity of the formulation may vary depending upon the stability requirements of the formulation or for the route of administration, in many instances, particularly in formulations for subcutaneous administration, it is important that the formulation have approximately the same osmotic pressure (i.e., isotonic) as the cellular fluid (i.e., within approx. 50 mOsm). Therefore, a pharmaceutical formulation, particularly for subcutaneous administration, should have an osmotic pressure between about 250 mOsm and about 350 mOsm.
  • the tonicity modifier is added to the liquid formulation before freeze- drying. In other instances, the tonicity modifier is added along with the diluent during reconstitution of the freeze-dried formulation.
  • Excipients such as mannitol, sucrose, glycine, glycerol and sodium chloride are good tonicity adjusters.
  • Buffers are typically included in pharmaceutical formulations to maintain the pH of the formulation at a physiologically acceptable pH.
  • the desirable pH for a formulation may also be affected by the active agent.
  • most biopharmaceutical active agents have a higher activity within a specific pH range.
  • the pH of the formulation is maintained between about 4.0 and about 8.0, between about 5.5 and about 7.5, or between about 6.0 and about 7.2.
  • the buffer is included in the liquid formulation at a concentration between about 2 mM to about 50 mM, or between about 10 mM and 25 mM.
  • Suitable buffers include buffers derived from an acid such as phosphate, aconitic, citric, gluaric, malic, succinic and carbonic acid. Typically, the buffer is employed as an alkali or alkaline earth salt of one of these acids. Frequently the buffer is phosphate or citrate, often citrate, for example sodium citrate or citric acid. Other suitable buffers include acetate, Tris and histidine buffers.
  • the freeze-dried formulation of the invention is suitable for parenteral administration, including intravenous, subcutaneous and intramuscular administration.
  • Example 1 Preparation of Monoclonal Antibody in Sucrose Formulation.
  • a monoclonal IgG antibody (MW 150-160 kDa) was recombinantly produced using a standard mammalian cell line. Bulk drug substance was then obtained by purifying the monoclonal antibody from the cell culture supernatant using standard purification techniques.
  • the monoclonal antibody was diluted to the target concentration (i.e., 0 mg/mL, 10 mg/nxL, 20 mg/mL, 40 mg/mL, 60 mg/mL, 80 mg/niL, and 100 mg/mL) using a formulation buffer that included 10 mM citrate, 8% sucrose, and 0.04% Polysorbate-80 at a pH of 6.5. Protein concentration was monitored by measuring absorbance at A 280 .
  • Bovine Serum Albumin (BSA) was purchased from Sigma (part #A2153). BSA was measured out by weight and dissolved in a formulation buffer containing 10 mM citrate, 8% sucrose, and 0.04% Polysorbate-80, pH 6.5. BSA was diluted with the formulation buffer to varying concentrations: 10 mg/mL, 20 mg/mL, 40 mg/mL, 60 mg/mL, 80 mg/mL, and 100 mg/mL.
  • Bovine Serum Albumin (BSA) was purchased from Sigma (part #A2153). BSA was measured out by weight and dissolved in a formulation buffer containing 10 mM phosphate, 2% sorbitol, and 0.02% Polysorbate-80, pH 7.2. BSA was diluted with the formulation buffer to varying concentrations: 10 mg/mL, 20 mg/mL, 40 mg/mL, 60 mg/mL, 80 mg/mL, and 100 mg/mL.
  • DSC Differential Scanning Calorimetry
  • DSC Differential Scanning Calorimetry
  • RCS refrigerated cooling system
  • the formulations included varying protein concentrations to determine the effect of protein concentration on the glass transition temperature (Tg').
  • concentrations used were 0 mg/mL, 10 mg/mL, 20 mg/mL, 40 mg/mL, 60 mg/mL, 80 mg/mL, and 100 mg/mL.
  • the samples were run in duplicate, at minimum, and an average was taken.
  • Freeze dry microscopy studies were performed using liquid monoclonal antibody samples and liquid BSA samples, prepared as described in Examples 1 - 3, with varying protein concentrations to determine the effect of protein concentration on collapse temperature. The concentrations used were 0 mg/mL, 10 mg/mL, 20 mg/mL, 40 mg/mL, 60 mg/mL, 80 mg/mL, and 100 mg/mL. Freeze-dry microscopy runs were performed in duplicate.
  • Tables 4 - 6 show the temperature at which an initial structural change (or change in the initial appearance) was observed (onset of collapse), and the temperature at which collapse became clearly evident (i.e., the initial structural appearance was totally absent). Tg' is also shown in these tables for comparison.
  • Figure 8 shows "snapshots" of the freeze-dry microscopy run for a 80 mg/mL sample of monoclonal antibody taken over a sequence of time as the temperature of the product was gradually increased. Frozen material is on the right side of each panel and dried material is on the left. The drying front gradually moves from left to right. As shown in Figure 8: (A) -24°C was a temperature prior to any change, i.e. demonstrating the "initial appearance"; (B) -19°C was observed as the onset temperature; (C) -12°C was observed as the collapse temperature; and (D) -7°C was observed as the solution melting temperature.
  • Tg' for the sucrose containing formulations were similar to the onset temperature at protein concentrations up to about 40 mg/ml through 60 mg/ml.
  • the 80 mg/ml monoclonal antibody sample showed a collapse temperature (-12 0 C), which was 14 0 C higher than its Tg', and an onset temperature (-19 0 C) that was 7 0 C higher than its Tg'. This suggests that for formulations with high protein concentration, the generalization that Tg' is closely associated with collapse temperature may not be applicable.
  • thermocouples Omega, Part # 5SRTC-TT-T-30-36.
  • the majority of samples freeze-dried using this cycle showed a product temperature below the collapse temperature (as measured by freeze-dry microscopy) throughout the primary drying, and the cakes showed no visual signs of collapse.
  • the sorbitol containing formulation with 0 mg/mL BSA showed a product temperature that exceeded collapse temperature (determined by freeze-dry microscopy) throughout primary drying.
  • the cakes for the 0 mg/mL samples were completely collapsed following freeze-drying as shown in Figure 9.
  • the product temperature for the sorbitol containing formulation with 10 mg/mL BSA also exceeded the collapse temperature for a portion of primary drying, and the cakes showed partial collapse (Figure 9).
  • the other sorbitol containing formulations (containing BSA from 20 mg/mL to 100 mg/mL) showed little or no signs of collapse.
  • the product temperature for these formulations were below the collapse temperature (or in some cases just at collapse temperature). All of these samples exceeded Tg' and in some cases T 0 during the primary drying process. This is consistent with increased protein concentration allowing for drying above the Tg' and To-
  • freezing rate was also 0.3 0 C per minute, but primary drying was performed with higher shelf temperatures ranging from -5 0 C to as high as 3O 0 C and chamber pressures ranged from 100 mTorr to 225 mTorr.
  • the maximum product primary drying temperature under the aggressive conditions was above Tg' in all cases and above both Tg' and To in some cases.
  • Secondary drying conditions varied under the more aggressive cycle conditions, with a shelf temperature from 30 to 35 0 C and chamber pressure ranging from 100 mTorr to 225 mTorr.
  • Stability indicating assays were available for the monoclonal antibody. SEC- HPLC was used to monitor protein aggregation. Samples that were dried under conservative conditions had an equivalent percentage of aggregation to those dried under aggressive conditions. The percentage of aggregate for each of these samples was equivalent to the percentage of aggregate in the starting material prior to freeze-drying. That is, regardless of whether the maximum primary drying product temperature was above or below Tg' and To, the stability indicating assays showed an equivalent profile. This included samples that had a maximum product primary drying temperature as high as -16 0 C, which was 3 0 C higher than the To and 1O 0 C higher than Tg'.
  • samples freeze-dried with a primary drying shelf temperature of -25 0 C yielding a maximum product primary drying temperature of -28 0 C
  • samples freeze-dried with a primary drying shelf temperature of O 0 C maximum product primary drying temperature of -2O 0 C. Therefore, maximum product primary drying temperature was either below or above Tg' for these cycles, respectively.
  • These samples were compared by multiple stability indicating assays over a period of 3 months. These samples were also compared at 6-, 9-, and 12-months for stability using multiple stability indicating assays.
  • SEC-HPLC was used to monitor aggregation, relative binding of the monoclonal antibody to its antigen was measured by ELISA, and the relative potencies of the monoclonal antibody samples were measured by an inhibition of binding assay.
  • Reduced SDS-PAGE was used to monitor protein fragmentation, and IEC-HPLC was used to monitor charge heterogeneity. Regardless of whether the maximum primary drying product temperature was above or below Tg', samples were comparable at each time point of the study for all assays tested.
  • FTIR spectra were recorded on an ABB Bomem MB 104 series Fourier- transform infrared spectrometer equipped with a DTGS detector. The instrument was purged continuously with dry nitrogen to minimize water vapor. Both liquid and powder samples were collected on a SensIR Technologies DuraSamplIR II attenuated total reflection accessory fitted with a diamond triple-bounce internal reflection element. A total of 32 scans were collected for each spectrum at a resolution of 4 cm "1 .
  • ATR -log(R/Ro) in GRAMS software (Thermo Galactic GRAMS/32 AI, v. 6.01). Spectra were interactively corrected for liquid water and water vapor, as appropriate, and then baseline- and offset-corrected between 1715-1590 cm “1 (amide I). Spectra were corrected for concentration by normalizing the amide I area to 1.0. Difference spectra were calculated by subtracting the spectrum of the final drug product minus the parent bulk liquid spectrum. The areas of the difference spectra were quantified by integration in GRAMS.
  • the extent of the changes caused by the two lyophilization cycles can be quantified by calculating the area of the negative bands, which, because the spectra are area-normalized to 1.0, represents the percentage of change from native structure. For the conservative cycle, the difference is 8.6%, while for the aggressive cycle, the difference is 8.8%. The error of the measurements was determined to be approximately 0.7%, based on the area of the difference between spectra of multiple preparations of the same sample. Therefore, within error, the aggressive and conservative cycles induce the same secondary structural changes to the protein, relative to the liquid state, and to the same extent. Based on these results, it is expected that both cycles should have the same impact on the physical stability of the lyophilized product.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur des procédés de lyophilisation de préparations pharmaceutiques selon lesquels pendant la première étape de dessiccation la température du produit doit être supérieure à sa température de transition vitreuse (Tg') ou supérieure à sa température de transition vitreuse (Tg') et à la température de début d'effondrement (TO), mais inférieure à la température d'effondrement (Tc). L'invention porte également sur une préparation pharmaceutique présentant une concentration en protéines d'au moins environ 20 mg/ml, et sur une préparation pharmaceutique contenant peu ou pas d'agent gonflant cristallin et/ou au moins environ 2 % w/v de disaccharide.
PCT/US2006/002696 2005-01-27 2006-01-26 Preparation pharmaceutique WO2006081320A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64701105P 2005-01-27 2005-01-27
US60/647,011 2005-01-27

Publications (2)

Publication Number Publication Date
WO2006081320A2 true WO2006081320A2 (fr) 2006-08-03
WO2006081320A3 WO2006081320A3 (fr) 2006-10-12

Family

ID=36741034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002696 WO2006081320A2 (fr) 2005-01-27 2006-01-26 Preparation pharmaceutique

Country Status (1)

Country Link
WO (1) WO2006081320A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017296A1 (fr) * 2008-08-05 2010-02-11 Wyeth Lyophilisation au-dessus de la température d’effondrement
WO2011082196A3 (fr) * 2009-12-30 2011-09-15 Baxter International Inc. Reconstitution rapide de suspensions pharmaceutiques lyophilisées
US9085619B2 (en) 2007-11-30 2015-07-21 Abbvie Biotechnology Ltd. Anti-TNF antibody formulations
EP2916090A1 (fr) * 2014-02-04 2015-09-09 Project Pharmaceutics GmbH Lyophilisat de fluide
US11773134B2 (en) * 2015-09-17 2023-10-03 Annexin Pharmaceuticals Ab Process of manufacture of annexin V

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565651A (en) * 1982-10-07 1986-01-21 The Green Cross Corporation Method of lyophilizing cold insoluble globulin
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20010014326A1 (en) * 1995-07-27 2001-08-16 Genentech, Inc. Protein formulation
US20040180827A1 (en) * 2003-01-08 2004-09-16 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565651A (en) * 1982-10-07 1986-01-21 The Green Cross Corporation Method of lyophilizing cold insoluble globulin
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20010014326A1 (en) * 1995-07-27 2001-08-16 Genentech, Inc. Protein formulation
US20040180827A1 (en) * 2003-01-08 2004-09-16 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BORQUE L. ET AL.: 'Addition of Sucrose Avoids Effect of Lyophilization on Determinations of Lipoprotein(a) in Serum' CLINICAL CHEMISTRY vol. 39, no. 3, 1993, pages 553 - 554, XP003000311 *
FONSECA F. ET AL.: 'Collapse Temperature of Freeze-Dried Lactobacillus bulgaricus Suspensions and Protective Media' BIOTECHNOLOGY PROGRESS vol. 20, no. 1, 2004, pages 229 - 238, XP003000312 *
RAMBHATLA S. ET AL.: 'Cake Shrinkage During Freeze Drying: A Combined Experimental and Theoretical Study' PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY vol. 1, 2005, pages 33 - 40, XP008068192 *
SGOUTAS D.S. ET AL.: 'Effect of Lyophilization on Determination of Lipoprotein(a) in Serum' CLINICAL CHEMISTRY vol. 38, no. 7, 1992, pages 1355 - 1360, XP003000310 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085619B2 (en) 2007-11-30 2015-07-21 Abbvie Biotechnology Ltd. Anti-TNF antibody formulations
US11167030B2 (en) 2007-11-30 2021-11-09 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US11191834B2 (en) 2007-11-30 2021-12-07 Abbvie Biotechnology Ltd Protein formulations and methods of making same
WO2010017296A1 (fr) * 2008-08-05 2010-02-11 Wyeth Lyophilisation au-dessus de la température d’effondrement
US20100041870A1 (en) * 2008-08-05 2010-02-18 Wyeth Lyophilization above collapse
US9884019B2 (en) 2008-08-05 2018-02-06 Wyeth Llc Lyophilization above collapse
WO2011082196A3 (fr) * 2009-12-30 2011-09-15 Baxter International Inc. Reconstitution rapide de suspensions pharmaceutiques lyophilisées
EP2916090A1 (fr) * 2014-02-04 2015-09-09 Project Pharmaceutics GmbH Lyophilisat de fluide
US11773134B2 (en) * 2015-09-17 2023-10-03 Annexin Pharmaceuticals Ab Process of manufacture of annexin V

Also Published As

Publication number Publication date
WO2006081320A3 (fr) 2006-10-12

Similar Documents

Publication Publication Date Title
US20070196364A1 (en) Pharmaceutical Formulation and Process
EP1982133B1 (fr) Procédé visant à induire la nucléation d'un materiau
Thakral et al. Stabilizers and their interaction with formulation components in frozen and freeze-dried protein formulations
EP3136030B1 (fr) Procédé de lyophilisation
WO2006014965A2 (fr) Preparation pharmaceutique et processus
Horn et al. Impact of fast and conservative freeze-drying on product quality of protein-mannitol-sucrose-glycerol lyophilizates
WO2005025499A2 (fr) Compositions hydrophobes de medicaments, contenant un activateur de reconstitution
AU2005225000A1 (en) Lyophilization method to improve excipient crystallization
WO2006081320A2 (fr) Preparation pharmaceutique
WO2006029467A1 (fr) Traitement de lyophylisation rapide
Teagarden et al. Practical aspects of freeze-drying of pharmaceutical and biological products using nonaqueous cosolvent systems
Bosch Aggressive freeze-drying: a fast and suitable method to stabilize biopharmaceuticals
Moran et al. Adjusting and understanding the properties and crystallisation behaviour of amorphous trehalose as a function of spray drying feed concentration
EP2916090A1 (fr) Lyophilisat de fluide
JP2988631B2 (ja) ホスホマイシンナトリウムの凍結乾燥製剤およびその製造法
Jameel Overview of Freeze Drying
US20040007689A1 (en) Process for controlling the hydrate mix of a compound
Nail Stability considerations in development of freeze-dried pharmaceuticals
Nail 13 Stability considerations in development
Karel et al. Mechanisms of deterioration of nutrients phase 1
WO2004007507A1 (fr) Procede de regulation du melange d'hydrates d'un compose
MX2008009384A (en) Method of inducing nucleation of a material

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 06719529

Country of ref document: EP

Kind code of ref document: A2